ChemoCentryx Inc CCXI gained more than 70 percent Friday on news that its lead drug candidate met with success in a Phase II study.
Shares of the company changed hands recently at $7.57, up 68 percent.
Chief Executive Thomas J. Schall said results will enable the launch of a Phase III trial, and that the company is ""well-positioned to advance partnering discussions" concerning the drug.
The company's CCX140 treatment for diabetic nephropathy, a form of kidney disease, met its primary end point and was found to improve certain chemical measures associated with a risk of decreased kidney function.
The year-long trial, involving 332 patients in Europe, didn't raise safety issues that would prevent further trials.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.